Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palbociclib - Onyx Pharmaceuticals/Pfizer

X
Drug Profile

Palbociclib - Onyx Pharmaceuticals/Pfizer

Alternative Names: IBRANCE; Ibrance; Iburance; Parvociclib; PD-0332991; PD-332991; PD-991; PF-332991

Latest Information Update: 22 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyx Pharmaceuticals; Pfizer; SOLTI Breast Cancer Research Group
  • Developer Assistance Publique Hopitaux de Paris; Bergonie Institute; Calithera Biosciences; Canadian Cancer Trials Group; Celgene Corporation; Dana-Farber Cancer Institute; Emory University; European Organisation for Research and Treatment of Cancer; Georgetown University; German Breast Group; Grupo Espanol de Tumores Neuroendocrinos; GSK; International Breast Cancer Study Group; iOMEDICO AG; Karolinska Institute; National Cancer Institute (USA); Northwestern University; Pfizer; UNC Lineberger Comprehensive Cancer Center; UNICANCER; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class 2 ring heterocyclic compounds; Antineoplastics; Cyclopentanes; Ketones; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III HER2 negative breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Bone metastases; Brain metastases; Gastrointestinal stromal tumours; Mantle-cell lymphoma; Pancreatic cancer; Prostate cancer; Squamous cell cancer; Urogenital cancer
  • Phase I/II Colorectal cancer; Malignant melanoma
  • No development reported Acute myeloid leukaemia; Glioblastoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Discontinued Astrocytoma; Glioma

Most Recent Events

  • 16 May 2024 Updated efficacy, pharmacodynamics and adverse event data from the phase I/II VERITAC trial in HER2-negative-breast-cancer released by Arvinas
  • 01 Mar 2024 University of Kansas Medical Center and Pfizer terminate a phase I/II trial in HER2-positive Breast Cancer in USA (PO) due to low accrual (NCT03709082)
  • 06 Dec 2023 Georgetown University terminates phase II trial in Breast cancer (Monotherapy, Neoadjuvant therapy) in USA (PO), due to lack of accrual (NCT03535506)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top